Drug Profile

OR 070

Alternative Names: OR-070

Latest Information Update: 28 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orphagen Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Orphan nuclear receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Adrenocortical carcinoma

Most Recent Events

28 Apr 2024 No recent reports of development identified for preclinical development in Adrenocortical-carcinoma in USA (PO)
28 Mar 2020 Preclinical trials in Adrenocortical carcinoma in USA (PO) before March 2020
28 Mar 2020 Pharmacodynamics and pharmacokinetics data from preclinical studies in Adrenocortical carcinoma presented at the 102^nd Annual Meeting of the Endocrine Society (ENDO-2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com